

Information for Pharmacists

Claims Submission Procedure – Edoxaban 15mg and 30mg Tablets

Effective June 25, 2025 Updated July 9, 2025

Please include this Procedure in your Drug Programs Information Network (DPIN) Manual under Section 4: Claims Submission.

Pharmacies do NOT receive drug interaction information when submitting claims using PINs. Please review all claims carefully prior to submitting

- There is variable supply of the following products:
 - Lixiana (Edoxaban) 15mg Tablet (DIN: 02458640)
 - Lixiana (Edoxaban) 30mg Tablets (DIN: 02458659)
 - Lixiana (Edoxaban) 60mg Tablets (DIN: 02458667)
- Due to this shortage, Manitoba is outlining the following product selection tree. This selection tree is to encourage pharmacy providers to use existing commercial supply while outlining an alternative option if supply is unavailable:
 - Commercially available product should be dispensed if the pharmacy has inventory on hand or can obtain product through normal distribution channels;
 - The pharmacy vendor may obtain commercially available product from another provider (e.g., another member within the same chain);
 - o If commercially available Lixiana cannot be obtained, then the following PINs should be used when submitting claims for the generic options:

Brand	DIN	Drug/Format	PIN
Teva	02554208	Edoxaban 15mg Tablets	00912105
	02554216	Edoxaban 30mg Tablets	00912106
	02554224	Edoxaban 60mg Tablets	00912112
Sandoz	02553414	Edoxaban 15mg Tablets	00912107
	02553422	Edoxaban 30mg Tablets	00912108
	02553430	Edoxaban 60mg Tablets	00912111
Jamp	02557282	Edoxaban 30mg Tablets	00912109
	02557290	Edoxaban 60mg Tablets	00912113

Manitoba will inform pharmacy providers once the shortage has been resolved, and the PIN
is no longer required and has been withdrawn for coverage.

If your questions are not answered by reviewing the Claims Submission Procedures and FAQs posted at:

https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html

Please send an e-mail to NIBDrugShortages@gov.mb.ca.